Posted by Michael Wonder on 20 Sep 2025
Elinzanetant recommended for approval in EU as treatment of moderate to severe vasomotor symptoms
19 September 2025 - Positive opinion by the CHMP is based on the results from the clinical development Phase 3 studies OASIS 1-4.
The CHMP of the EMA has recommended elinzanetant for marketing authorisation in the European Union.
